Abiomed CEO and leadership

I am the Chief Executive Officer, President and Chairman of Abiomed, Inc. (NASDAQ: ABMD), the only medical device company focused solely on heart recovery. At Abiomed, we are driven by our four principles: recovering hearts and saving lives, leading in technology and innovation, growing shareholder value and sustaining a winning culture of putting patients first. As a U.S. military veteran, I also serve as Co-Founder and Chairman of the Mentoring Veterans Program (MVPvets), a nonprofit organization committed to helping military veterans network with industry mentors to discover career opportunities in the life sciences industry.

Mr. Todd A. Trapp joined Abiomed from Watts Water Technologies, Inc., a $1.5B global manufacturing leader of innovative products to control the efficiency, safety and quality of water within residential and commercial applications, where he served as CFO since 2015. Prior to joining Watts Water Technologies, Mr. Trapp spent 13 years in a variety of financial and operational roles at Honeywell International Inc., a $40B diversified technology and manufacturing company. At Honeywell, Mr. Trapp served as Vice President of Financial Planning and Analysis, Chief Financial Officer of the Airlines Business Unit, Director of Finance for the Transportation Systems Division, Investor Relations Manager and other senior finance positions. Prior to joining Honeywell, Mr. Trapp held several treasury and finance operational roles at United Business Media, Inc. and Pearson, Inc. Mr. Trapp holds a BS in Accounting from Providence College and an MBA in Finance from Northeastern University.

Andrew Greenfield is a VP/Chief Commercial Ofcr at ABIOMED INC. He has experience at GE Healthcare and has worked as VP & Gen Mgr:Global Marketing at ABIOMED INC. Andrew studied at University of Illinois and St Louis University.

Chuck led the Interventional Cardiology program at the Sanger Clinic in Charlotte, NC for 20 years and founded the Carolinas Cardiovascular Foundation for research and education. He was CMO of Abbott Vascular from 2007-2019 highlighted by FDA and global approvals of carotid stenting, MitraClip, and Absorb BVS. He is now the CMO and VP of Global Clinical and Medical Affairs at Abiomed, Inc, Danvers, MA, USA. His passion now is to elevate the practice guidelines for MCS in high-risk PCI and AMI shock such that more patients with severe chronic or acute CAD conditions can benefit with improved quality of life and clinical outcomes.

Dr. Thorsten Siess is a Chief Technology Officer at ABIOMED INC and is based in United States.

I am the Chief Executive Officer, President and Chairman of Abiomed, Inc. (NASDAQ: ABMD), the only medical device company focused solely on heart recovery. At Abiomed, we are driven by our four principles: recovering hearts and saving lives, leading in technology and innovation, growing shareholder value and sustaining a winning culture of putting patients first. As a U.S. military veteran, I also serve as Co-Founder and Chairman of the Mentoring Veterans Program (MVPvets), a nonprofit organization committed to helping military veterans network with industry mentors to discover career opportunities in the life sciences industry.